Editorial: New drugs for HIV: quo vadis?

IF 4.5 3区医学 Q2 IMMUNOLOGY

Current Opinion in HIV and AIDS Pub Date : 2022-01-01 DOI:10.1097/COH.0000000000000710

Charles W Flexner, Angela Kashuba

引用次数: 0

Abstract

The WHO estimates that by the beginning of 2021, 27.5 million adults and children were receiving antiretroviral treatment [1]. Many of these individuals are taking a coformulated generic combination of dolutegravir with tenofovir disoproxil fumarate (TDF) and lamivudine (TLD), a daily oral combination that could be thought of as the ‘universal antiretroviral regimen [2]’. In the face of numbers like this, one could easily wonder if there is even a need for new treatments for HIV. Although it has been more than 3 years since this journal reviewed the topic of ‘New Drugs for HIV’, the Table of

查看原文本刊更多论文

社论:艾滋病新药:现状如何?

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in HIV and AIDS IMMUNOLOGY-INFECTIOUS DISEASES

CiteScore

7.40

自引率

7.30%

发文量

115

审稿时长

6-12 weeks

期刊介绍： Published bimonthly and offering a unique and wide ranging perspective on the key developments in the field, each issue of Current Opinion in HIV and AIDS features hand-picked review articles from our team of expert editors. With six disciplines published across the year – including HIV and ageing, a HIV vaccine, and epidemiology – every issue also contains annotated reference detailing the merits of the most important papers.